Trial Profile
A retrospective study evaluating tumor responses and toxicities in patients with small cell lung cancer treated with second line nivolumab plus ipilimumab after chest radiotherapy and/or radiotherapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Oct 2018
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 11 Oct 2018 New trial record
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer